GEFARNATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H44O2
Molecular Weight	400.6371
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C

InChI

InChIKey=ZPACYDRSPFRDHO-ROBAGEODSA-N

InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+

HIDE SMILES / InChI

Molecular Formula	C27H44O2
Molecular Weight	400.6371
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	3
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18560615
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/4452287

Gefarnate is a drug used for the treatment of gastric ulcers. It also has been proposed for use in the treatment of dry eye syndrome, although for this disease it was discontinued in 2008. The mechanism of action consists of the normalisation of the mucous secretion, followed by the restoration of the normal defensive mucous barrier.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
positive regulation of mucus secretion 1 Target ID: GO:0070257 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4452287	Interacts 323

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dry eye syndrome 21 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18560615	Primary		Phase II 1132	Unknown Approved Use Unknown
Chronic erosive gastritis 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22932084	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms.	2012 Aug	22932084
Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models.	2013	23386781

Patents

Sample Use Guides

In Vivo Use Guide

treatment: 600 mg daily by mouth for 30 days

Route of Administration: Oral

In Vitro Use Guide

For the studies in vitro, cultured rat cornea sections (3 mm diameter) were incubated with radiolabeled sodium sulfate, rinsed, and then incubated for 30 min in the presence of the drug. Gefarnate significantly increased the mucin-like glycoprotein secretion from cultured rat corneas

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:25:59 GMT 2023` Edited by `admin` on `Fri Dec 15 15:25:59 GMT 2023`
Record UNII	1ISE2Y6ULA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEFARNATE

Official Name

English

GEFANIL

Brand Name

English

DA-688

Code

English

GEFARNATE [MART.]

Common Name

English

GEFARNATE [JAN]

Common Name

English

Gefarnate [WHO-DD]

Common Name

English

GEFARNATE [MI]

Common Name

English

TRANS-3,7-DIMETHYL-2,6-OCTADIENYL 5,9,13-TRIMETHYL-4,8,12-TETRADECATRIENOATE

Common Name

English

DA 688

Code

English

gefarnate [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A02BX07